Dosage regimes for the administration of an Anti-CD137 / PD-l1 antigen-binding protein

WO2025242842A1PCT designated stage Publication Date: 2025-11-27INVOX PHARMA LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2025/064221
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-05-22
Filing Date
2025-05-22
Publication Date
2025-11-27

Smart Images

  • Figure EP2025064221_27112025_PF_FP_ABST
    Figure EP2025064221_27112025_PF_FP_ABST
Patent Text Reader

Abstract

The present application relates to dosage regimes for the administration of an antigen-binding protein which binds CD137 and programmed death-ligand 1 (PD-L1) and their medical use in the treatment of cancer in human patients.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Antibody molecules that bind PD-l1 and CD137

    WO2020011964A1

  • Fc binding fragments comprising CD137 antigne binding side

    WO2020011972A1

  • Antibody molecules

    WO2020011973A1

  • US63650742P